Towards understanding the role of nanomedicine in targeting TNFR2 in rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium and progressive joint destruction which significantly affects both quality of life and socioeconomic status. Admittedly, various treatments are available, but they are usually accompanied by vario...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Immunology Ročník 173; číslo 4; s. 622 - 633
Hlavní autoři: Lambuk, Fatmawati, Nordin, Nor Asyikin, Mussa, Ali, Lambuk, Lidawani, Ahmad, Suhana, Hassan, Rosline, Kadir, Ramlah, Mohamud, Rohimah, Yahya, Nurul Khaiza
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Wiley Subscription Services, Inc 01.12.2024
Témata:
Animals
Antirheumatic Agents - therapeutic use
Apoptosis
Arthritis
Arthritis, Rheumatoid - drug therapy
autoimmune disease
Autoimmune diseases
Control equipment
Drug development
Health services
Humans
Inflammation
Molecular Targeted Therapy
Nanomedicine - methods
Nanoparticles
Nanoparticles - therapeutic use
Nanotechnology
Necroptosis
Pathophysiology
Precision medicine
Quality of life
Receptors, Tumor Necrosis Factor, Type II - antagonists & inhibitors
Receptors, Tumor Necrosis Factor, Type II - metabolism
Rheumatoid arthritis
Rheumatoid synovitis
Side effects
Signal Transduction - drug effects
Socioeconomics
Tumor necrosis factor
Tumor necrosis factor receptors
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - metabolism
Tumor necrosis factor-TNF
tumour necrosis factor receptor 2 (TNFR2)
tumour necrosis factor‐alpha (TNF‐α)
nanoparticles
autoimmune disease
rheumatoid arthritis
tumour necrosis factor receptor 2 (TNFR2)
tumour necrosis factor‐alpha (TNF‐α)
tumour necrosis factor-alpha (TNF-alpha)
ISSN:0019-2805, 1365-2567, 1365-2567
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation of the synovium and progressive joint destruction which significantly affects both quality of life and socioeconomic status. Admittedly, various treatments are available, but they are usually accompanied by various side effects, from mild to severe, and potentially with adverse events. Tumour necrosis factor‐alpha (TNF‐α) plays a crucial role in the pathophysiology of RA. It promotes inflammatory, apoptosis and necroptosis via TNF receptor‐1 (TNFR1) but elicit anti‐inflammatory effects via TNFR2. Herein, targeting TNFR2 has gained attention in RA studies. Understanding the role of nanomedicine in modulating TNFR2 signalling may be the instrument in development of RA therapies. Nanotechnology has made a significant progress in treating various conditions of diseases since its inception. Due to this, nanomedicine has emerged as a promising therapeutics approach for RA. Recent studies have demonstrated the potential of nanomedicine in RA theranostics, combining therapy and diagnostics for improved treatment outcomes. Owing to the challenges and advancements in the field of nanotechnology, nanoparticles are seen as an applicable candidate in the treatment of RA. In this review, we provide an overview of the role of nanomedicine in targeting TNFR2 for the treatment of RA and highlight the limitations of current therapies as well as the potential of nanocarriers with controlled drug release and active targeting abilities. Nanoparticles can direct T cells to develop into specific subsets when taken by antigen‐presenting cells. TNF‐α, a proinflammatory cytokine in rheumatoid arthritis disease, resembles to the expressed TNFR2 and triggers the activation of B cells, resulting in the inhibition of antibody production.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0019-2805
1365-2567
1365-2567
DOI:10.1111/imm.13855